Dole Sachinkumar S, Balan Arun, Gaikwad Nitin S
Respiratory Medicine, Dr. D. Y. Patil Medical College, Hospital & Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune, IND.
Respiratory Medicine, Maharashtra Institute of Medical Education and Research (MIMER) Medical College, Pune, IND.
Cureus. 2024 Jul 29;16(7):e65659. doi: 10.7759/cureus.65659. eCollection 2024 Jul.
Introduction Pleural effusion is a challenging diagnosis at times, especially due to the overlap of symptoms in effusions of various etiologies. In this study, we aimed to identify if pleural fluid adenosine deaminase (ADA) or serum C-reactive protein (CRP) can be used as an additional novel biomarker for ADA in diagnosing tubercular, parapneumonic, and malignant pleural effusions. Materials and methods A prospective, observational, cross-sectional study was conducted on 79 patients diagnosed with tubercular, parapneumonic, or malignant pleural effusion from August 2022 to April 2024 at the Department of Respiratory Medicine at Dr. D. Y. Patil Medical College, Hospital & Research Centre, Pimpri, Pune. The pleural fluid ADA/serum CRP ratio was identified in each group, and analysis was done to compare the ratio in each group. The correlation with pleural fluid ADA was also identified. Results A total of 79 patients were enrolled in this study. Out of these patients, 53 (67.1%) were identified as having tubercular pleural effusion, 10 (12.7%) patients had parapneumonic effusion, and 16 (20.3%) had malignant pleural effusion. For malignant effusions, the area under the curve (AUC) using the receiver operating characteristic (ROC) for the ADA/CRP ratio was observed to be 0.862. Sensitivity was 87.50% and specificity was 82.54% at a cut-off value of ≤0.5. The positive predictive value was found to be 56%, and the negative predictive value was found to be 96.3%. For parapneumonic effusions, the AUC using the ROC for the ADA/CRP ratio was observed to be 0.880. Sensitivity was 100% and specificity was 69.57% at a cut-off value of ≤0.67. The positive predictive value was found to be 32.3%, and the negative predictive value was found to be 100%. For tubercular effusions, the AUC using the ROC for the ADA/CRP ratio was observed to be 0.955. Sensitivity was 92.45% and specificity was 88.46% at a cut-off value of >0.54. The positive predictive value was found to be 94.2%, and the negative predictive value was found to be 85.2%. The Pearson correlation coefficient (r) of 0.633 indicates a moderately strong positive linear relationship between ADA and ADA/CRP levels. Conclusion The pleural fluid ADA-to-serum CRP ratio can be used as a useful diagnostic tool for differentiating between tubercular, parapneumonic, and malignant pleural effusions. ADA/CRP ratio has added diagnostic value over ADA. In clinically puzzling scenarios, the ADA/CRP ratio can be a cost-effective tool before opting for a more expensive and invasive procedure, which is also often difficult to obtain in resource-limited healthcare settings. More research with a larger sample size is indicated to incorporate the ADA/CRP ratio as an added diagnostic tool along with ADA.
引言
胸腔积液有时是一项具有挑战性的诊断,特别是由于各种病因导致的积液症状重叠。在本研究中,我们旨在确定胸腔积液腺苷脱氨酶(ADA)或血清C反应蛋白(CRP)是否可作为ADA的一种额外的新型生物标志物,用于诊断结核性、类肺炎性和恶性胸腔积液。
材料与方法
2022年8月至2024年4月,在浦那皮姆普里的DY帕蒂尔医学院、医院和研究中心呼吸内科,对79例诊断为结核性、类肺炎性或恶性胸腔积液的患者进行了一项前瞻性、观察性横断面研究。确定每组的胸腔积液ADA/血清CRP比值,并进行分析以比较每组的比值。还确定了与胸腔积液ADA的相关性。
结果
本研究共纳入79例患者。其中,53例(67.1%)被确定为结核性胸腔积液,10例(12.7%)患者为类肺炎性积液,16例(20.3%)为恶性胸腔积液。对于恶性积液,使用受试者工作特征(ROC)曲线的ADA/CRP比值的曲线下面积(AUC)为观察到为0.862。在临界值≤0.5时,敏感性为87.50%,特异性为82.54%。阳性预测值为56%,阴性预测值为96.3%。对于类肺炎性积液,使用ROC曲线的ADA/CRP比值的AUC为观察到为0.880。在临界值≤0.67时,敏感性为100%,特异性为69.57%。阳性预测值为32.3%,阴性预测值为100%。对于结核性积液,使用ROC曲线的ADA/CRP比值的AUC为观察到为0.955。在临界值>0.54时,敏感性为92.45%,特异性为88.46%。阳性预测值为94.2%,阴性预测值为85.2%。皮尔逊相关系数(r)为0.633,表明ADA与ADA/CRP水平之间存在中度强正线性关系。
结论
胸腔积液ADA与血清CRP的比值可作为区分结核性、类肺炎性和恶性胸腔积液的有用诊断工具。ADA/CRP比值相对于ADA具有额外的诊断价值。在临床疑难情况下,ADA/CRP比值可以是在选择更昂贵和侵入性更强的检查之前的一种经济有效的工具,而在资源有限的医疗环境中,这种检查通常也很难获得。需要进行更大样本量的更多研究,以将ADA/CRP比值作为ADA之外的一种额外诊断工具。